2,3,5-Tri-O-benzyl-D-ribono-1,4-lactone

2,3,5-Tri-O-benzyl-D-ribono-1,4-lactone is a purine nucleoside analog. 2,3,5-Tri-O-benzyl-D-ribono-1,4-lactone can be synthesized from D-ribose by reacting with methanol under Fischer glycosylation conditions. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. 2,3,5-Tri-O-benzyl-D-ribono-1,4-lactone exerts anticancer activities through inhibition of DNA synthesis, induction of apoptosis, etc. 2,3,5-Tri-O-benzyl-D-ribono-1,4-lactone can be studied in anticancer research for lymphoid malignancies[1][2].

Product Specifications

CAS Number

[55094-52-5]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Nucleoside Antimetabolite/Analog

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/2-3-5-tri-o-benzyl-d-ribono-1-4-lactone.html

Concentration

10mM

Purity

99.95

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C1O[C@H](COCC2=CC=CC=C2)[C@@H](OCC3=CC=CC=C3)[C@H]1OCC4=CC=CC=C4

Molecular Formula

C26H26O5

Molecular Weight

418.49

Precautions

H302, H315, H319, H335

References & Citations

[1]Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18 (23) :3373-88.|[2]Mallikharjuna Rao Lambu et al., Synthesis of C-spiro-glycoconjugates from sugar lactones via zinc mediated Barbier reaction. RSC Adv., 2014, 4, 11023-11028.